Literature DB >> 32619565

TRPM4 inhibition improves spatial memory impairment and hippocampal long-term potentiation deficit in chronic cerebral hypoperfused rats.

Nurul Aqmar Mohamad Nor Hazalin1, Ping Liao2, Zurina Hassan3.   

Abstract

Chronic cerebral hypoperfusion (CCH) been well characterized as a common pathological status contributing to neurodegenerative diseases such as Alzheimer's disease and vascular dementia. CCH is an important factor that leads to cognitive impairment, but the underlying neurobiological mechanism is poorly understood and no effective treatment is available. Recently, transient receptor potential melastatin 4 (TRPM4) cation channel has been identified as an important molecular element in focal cerebral ischemia. Over activation of the channel is a major molecular mechanism of oncotic cell death. However, the role of TRPM4 in CCH that propagates global brain hypoxia have not been explored. Therefore, the present study is designed to investigate the effect of TRPM4 inhibition on the cognitive functions of the rats following CCH via permanent bilateral occlusion of common carotid arteries (PBOCCA) model. In this model, treatment with siRNA suppressed TRPM4 expression at both the mRNA and protein levels and improved cognitive deficits of the CCH rats without affecting their motor function. Furthermore, treatment with siRNA rescued the LTP impairment in CCH-induced rats. Consistent with the restored of LTP, western blot analysis revealed that siRNA treatment prevented the reduction of synaptic proteins, including calcium/calmodulin-dependent kinase II alpha (CaMKIIα) and brain-derived neurotrophic factor (BDNF) in brain regions of CCH rats. The present findings provide a novel role of TRPM4 in restricting cognitive functions in CCH and suggest inhibiting TRPM4 may represent a promising therapeutic strategy in targeting ion channels to prevent the progression of cognitive deficits induced by ischemia.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic cerebral hypoperfusion; LTP; Morris water maze; PBOCCA; TRPM4

Year:  2020        PMID: 32619565     DOI: 10.1016/j.bbr.2020.112781

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  5 in total

1.  A glibenclamide-sensitive TRPM4-mediated component of CA1 excitatory postsynaptic potentials appears in experimental autoimmune encephalomyelitis.

Authors:  Brenna C Fearey; Lars Binkle; Daniel Mensching; Christian Schulze; Christian Lohr; Manuel A Friese; Thomas G Oertner; Christine E Gee
Journal:  Sci Rep       Date:  2022-04-09       Impact factor: 4.379

2.  Hemodynamic changes and neuronal damage detected by 9.4 T MRI in rats with chronic cerebral ischemia and cognitive impairment.

Authors:  Minghua Sun; Liangmiao Wu; Guangying Chen; Xukai Mo; Changzheng Shi
Journal:  Brain Behav       Date:  2022-06-10       Impact factor: 3.405

3.  Identification of the Potential Gene Regulatory Networks and Therapeutics in Aged Mice With Postoperative Neurocognitive Disorder.

Authors:  Wensi Wu; Yongpai Peng; Jiaxin Zhou; Xiaojun Zhang; Lin Cao; Wei-Jye Lin; Yanan Lu; Jing Wen; Zhi Wang
Journal:  Front Neurosci       Date:  2021-06-24       Impact factor: 4.677

4.  PPI-MASS: An Interactive Web Server to Identify Protein-Protein Interactions From Mass Spectrometry-Based Proteomics Data.

Authors:  Mariela González-Avendaño; Simón Zúñiga-Almonacid; Ian Silva; Boris Lavanderos; Felipe Robinson; Roberto Rosales-Rojas; Fabio Durán-Verdugo; Wendy González; Mónica Cáceres; Oscar Cerda; Ariela Vergara-Jaque
Journal:  Front Mol Biosci       Date:  2021-07-01

Review 5.  Pharmacological Modulation and (Patho)Physiological Roles of TRPM4 Channel-Part 1: Modulation of TRPM4.

Authors:  Zsigmond Máté Kovács; Csaba Dienes; Tamás Hézső; János Almássy; János Magyar; Tamás Bányász; Péter P Nánási; Balázs Horváth; Norbert Szentandrássy
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.